Dishman Carbogen Amcis Limited (NSE:DCAL)

Market Cap	32.91B
Revenue (ttm)	26.50B
Net Income (ttm)	-1.10B
Shares Out	156.78M
EPS (ttm)	-7.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,061
Average Volume	383,967
Open	207.40
Previous Close	206.30
Day's Range	206.31 - 212.79
52-Week Range	133.00 - 307.98
Beta	1.35
RSI	41.44
Earnings Date	May 26, 2025

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 1,132
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DCAL

Financial Performance

In 2023, Dishman Carbogen Amcis's revenue was 26.16 billion, an increase of 8.41% compared to the previous year's 24.13 billion. Losses were -1.53 billion, 414.9% more than in 2022.